prednisolone has been researched along with Carcinoma, Non-Small Cell Lung in 33 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here we describe a case of biopsy proven interstitial nephritis after moxifloxacin treatment." | 7.76 | Biopsy proven acute interstitial nephritis after treatment with moxifloxacin. ( Becker, J; Chatzikyrkou, C; Clajus, C; Hafer, C; Hamwi, I; Kielstein, JT, 2010) |
| "To evaluate the efficacy of a combined therapy of prednisolone and alprazolam for controlling cisplatin-induced delayed emesis, a study involving 14 non-small cell lung cancer patients receiving cisplatin (80 mg/m2) was conducted." | 7.68 | [A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis]. ( Horio, Y; Iwahara, T; Minami, H; Sakai, S; Shibagaki, T; Shimokata, K; Watanabe, A, 1990) |
| "Here we describe a case of biopsy proven interstitial nephritis after moxifloxacin treatment." | 3.76 | Biopsy proven acute interstitial nephritis after treatment with moxifloxacin. ( Becker, J; Chatzikyrkou, C; Clajus, C; Hafer, C; Hamwi, I; Kielstein, JT, 2010) |
| "To evaluate the efficacy of a combined therapy of prednisolone and alprazolam for controlling cisplatin-induced delayed emesis, a study involving 14 non-small cell lung cancer patients receiving cisplatin (80 mg/m2) was conducted." | 3.68 | [A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis]. ( Horio, Y; Iwahara, T; Minami, H; Sakai, S; Shibagaki, T; Shimokata, K; Watanabe, A, 1990) |
| "The purpose of this study is to compare the efficacy and safety of Gefitinib versus VMP in combination with three-dimensional conformal radiotherapy (3D-CRT) for multiple brain metastases from non-small cell lung cancer (NSCLC)." | 2.80 | Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from non-small cell lung cancer. ( Chen, S; Hao, Y; Li, B; Li, L; Liu, C; Ning, F; Wang, F; Yu, Z, 2015) |
| "Neutropenia is the main toxicity." | 2.69 | [Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology]. ( Bessa, EH; Lena, H; Paillotin, D; Pérol, M; Robinet, G; Schuller-Lebeau, MP; Taytard, A; Thomas, P; Vergnenègre, A, 2000) |
| "Immune checkpoint inhibitors (ICIs), particularly anti-PD-1 antibody, have dramatically changed cancer treatment; however, fatal immune-related adverse events (irAEs) can develop." | 1.62 | A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. ( Arai, J; Ariizumi, H; Hamada, K; Hirasawa, Y; Horiike, A; Imamura, CK; Ishida, H; Ishiguro, T; Iwamoto, S; Kiuchi, Y; Kobayashi, S; Kubota, Y; Matsui, H; Oguro, N; Ohkuma, R; Sakaki, M; Sambe, T; Shida, M; Shiozawa, E; Taniguchi, M; Tate, G; Tsunoda, T; Tsurutani, J; Uchida, N; Wada, S; Yoshimura, K, 2021) |
| "Tubulointerstitial nephritis was treated with 30 mg prednisolone, the dose of which was tapered to and maintained at 5 mg." | 1.56 | Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab. ( Fujioka, Y; Mitani, R; Oda, N; Oshiro, Y; Takata, I; Taki, T; Takigawa, N; Tokura, T, 2020) |
| " Several immune-mediated neurological adverse events associated with ICIs have been reported to date, such as Guillain-Barré syndrome." | 1.51 | Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. ( Kakumoto, T; Kanzaki, M; Kishi, K; Miyamoto, A; Mochizuki, S; Sakoh, T; Sato, K; Uesaka, Y, 2019) |
| "We describe the first report of acute eosinophilic pneumonia (AEP), which is known as Th2-associated pulmonary disease, triggered by nivolumab, an anti-PD-1 antibody, in an advanced non-small cell lung cancer patient." | 1.51 | A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient. ( Fujii, K; Ichiyasu, H; Iyama, S; Jodai, T; Kakiuchi, Y; Kimura, T; Saeki, S; Saruwatari, K; Sato, N; Sato, R; Tomita, Y; Yoshida, C, 2019) |
| "Oral prednisolone 20 mg/d was started to treat the PMR without giant-cell arteritis." | 1.51 | [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment]. ( Fujii, R; Imai, Y; Okazaki, K; Tanaka, M; Uchitani, K, 2019) |
| "We herein report a 78-year old man with squamous cell carcinoma of the lungs treated with pembrolizumab." | 1.51 | Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. ( Fujiwara, K; Iwamoto, Y; Kayatani, H; Minami, D; Okawa, S; Ozeki, T; Sato, K; Shibayama, T; Takada, K, 2019) |
| "We herein report a case of immune-related colitis induced by the long-term use of nivolumab." | 1.48 | Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer. ( Hattori, Y; Ito, S; Kawa, Y; Kono, Y; Negoro, S; Sakuma, T; Satouchi, M; Tohnai, R; Tsuda, M; Urata, Y; Yasuda, Y, 2018) |
| "Nine patients suffered from chronic obstructive pulmonary disease (COPD) before treatment, and 18 patients had a smoking history (median pack years: 48)." | 1.43 | Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-centre experience. ( Bremer, M; Christiansen, H; Dickgreber, N; Henkenberens, C; Janssen, S; Lavae-Mokhtari, M; Leni, K; Meyer, A, 2016) |
| "We report on two cases of anti-PD-1 pneumonitis in advanced NSCLC patients treated with nivolumab after its FDA approval." | 1.43 | Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. ( Awad, MM; Chambers, ES; Chong, CR; Gray, SW; Hatabu, H; Hodi, FS; Jänne, PA; Marcoux, JP; Nishino, M; Ramaiya, NH, 2016) |
| "On Day 25, he developed interstitial lung disease." | 1.40 | Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease. ( Funada, Y; Hori, S; Ishikawa, Y; Kobayashi, K; Nishimura, Y; Otera, H; Tachihara, M; Tamura, D, 2014) |
| "A diagnosis of gefitinib-induced interstitial lung disease was made, and administration of high-dose prednisolone (1 g/day of intravenous methylprednisolone for three consecutive days, followed by oral prednisolone at 50 mg/day) was started." | 1.36 | Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report. ( Goto, Y; Hojo, M; Kobayashi, N; Kudo, K; Takeda, Y, 2010) |
| "We describe herein two cases of acute interstitial pneumonitis after administration of docetaxel to patients suffering from metastatic non-small cell lung cancer." | 1.30 | [Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases]. ( Etienne, B; Guérin, JC; Nesme, P; Pérol, M; Robinet, G; Vuillermoz, S, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 3 (9.09) | 18.2507 |
| 2000's | 2 (6.06) | 29.6817 |
| 2010's | 20 (60.61) | 24.3611 |
| 2020's | 7 (21.21) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, YY | 1 |
| Rannikmäe, K | 1 |
| Steele, N | 1 |
| Sakoh, T | 1 |
| Kanzaki, M | 1 |
| Miyamoto, A | 1 |
| Mochizuki, S | 1 |
| Kakumoto, T | 1 |
| Sato, K | 2 |
| Uesaka, Y | 1 |
| Kishi, K | 1 |
| Hisamatsu, Y | 1 |
| Morinaga, R | 1 |
| Watanabe, E | 1 |
| Ohtani, S | 1 |
| Shirao, K | 1 |
| Taki, T | 1 |
| Oda, N | 1 |
| Fujioka, Y | 1 |
| Mitani, R | 1 |
| Tokura, T | 1 |
| Takata, I | 1 |
| Oshiro, Y | 1 |
| Takigawa, N | 1 |
| Katsui, K | 1 |
| Ogata, T | 1 |
| Watanabe, K | 1 |
| Katayama, N | 1 |
| Kuroda, M | 1 |
| Kiura, K | 1 |
| Hiraki, T | 1 |
| Maeda, Y | 1 |
| Toyooka, S | 1 |
| Kanazawa, S | 1 |
| Lo, Y | 1 |
| Wu, WH | 1 |
| Gupta, S | 1 |
| Xu, D | 1 |
| Hadfield, J | 1 |
| Prentice, D | 1 |
| Skribek, M | 1 |
| Rounis, K | 1 |
| Afshar, S | 1 |
| Grundberg, O | 1 |
| Friesland, S | 1 |
| Tsakonas, G | 1 |
| Ekman, S | 1 |
| De Petris, L | 1 |
| Hirasawa, Y | 1 |
| Yoshimura, K | 1 |
| Matsui, H | 1 |
| Kubota, Y | 1 |
| Ishida, H | 1 |
| Arai, J | 1 |
| Sakaki, M | 1 |
| Oguro, N | 1 |
| Shida, M | 1 |
| Taniguchi, M | 1 |
| Hamada, K | 1 |
| Ariizumi, H | 1 |
| Ishiguro, T | 1 |
| Ohkuma, R | 1 |
| Sambe, T | 1 |
| Horiike, A | 1 |
| Imamura, CK | 1 |
| Shiozawa, E | 1 |
| Wada, S | 1 |
| Tsurutani, J | 1 |
| Iwamoto, S | 1 |
| Uchida, N | 1 |
| Kiuchi, Y | 1 |
| Tate, G | 1 |
| Kobayashi, S | 1 |
| Tsunoda, T | 1 |
| Hasegawa, Y | 1 |
| Kawai, S | 1 |
| Ota, T | 1 |
| Tsukuda, H | 1 |
| Fukuoka, M | 1 |
| Kiriu, T | 1 |
| Tamura, D | 2 |
| Tachihara, M | 3 |
| Sekiya, R | 1 |
| Hazama, D | 1 |
| Katsurada, M | 1 |
| Nakata, K | 2 |
| Nagano, T | 2 |
| Yamamoto, M | 2 |
| Kamiryo, H | 1 |
| Kobayashi, K | 3 |
| Nishimura, Y | 3 |
| Yasuda, Y | 1 |
| Urata, Y | 1 |
| Tohnai, R | 1 |
| Ito, S | 1 |
| Kawa, Y | 1 |
| Kono, Y | 1 |
| Hattori, Y | 1 |
| Tsuda, M | 1 |
| Sakuma, T | 1 |
| Negoro, S | 1 |
| Satouchi, M | 1 |
| Jodai, T | 1 |
| Yoshida, C | 1 |
| Sato, R | 1 |
| Kakiuchi, Y | 1 |
| Sato, N | 1 |
| Iyama, S | 1 |
| Kimura, T | 1 |
| Saruwatari, K | 1 |
| Saeki, S | 1 |
| Ichiyasu, H | 1 |
| Fujii, K | 1 |
| Tomita, Y | 1 |
| Imai, Y | 1 |
| Tanaka, M | 1 |
| Fujii, R | 1 |
| Uchitani, K | 1 |
| Okazaki, K | 1 |
| Okawa, S | 1 |
| Kayatani, H | 1 |
| Fujiwara, K | 1 |
| Ozeki, T | 1 |
| Takada, K | 1 |
| Iwamoto, Y | 1 |
| Minami, D | 1 |
| Shibayama, T | 1 |
| Murakami, S | 1 |
| Onishi, A | 1 |
| Umezawa, K | 1 |
| Katsurada, N | 1 |
| Yamada, T | 1 |
| Masuda, T | 1 |
| Yamaguchi, K | 1 |
| Sakamoto, S | 1 |
| Horimasu, Y | 1 |
| Miyamoto, S | 1 |
| Nakashima, T | 1 |
| Iwamoto, H | 1 |
| Hirata, S | 1 |
| Fujitaka, K | 1 |
| Hamada, H | 1 |
| Sugiyama, E | 1 |
| Hattori, N | 1 |
| Pattison, DA | 1 |
| Hofman, MS | 1 |
| Lau, E | 1 |
| Ware, R | 1 |
| Hicks, RJ | 1 |
| Ishikawa, Y | 1 |
| Hori, S | 1 |
| Otera, H | 1 |
| Funada, Y | 1 |
| Wang, F | 1 |
| Ning, F | 1 |
| Liu, C | 1 |
| Hao, Y | 1 |
| Li, L | 1 |
| Yu, Z | 1 |
| Chen, S | 1 |
| Li, B | 1 |
| Henkenberens, C | 1 |
| Janssen, S | 1 |
| Lavae-Mokhtari, M | 1 |
| Leni, K | 1 |
| Meyer, A | 1 |
| Christiansen, H | 1 |
| Bremer, M | 1 |
| Dickgreber, N | 1 |
| Nishino, M | 1 |
| Chambers, ES | 1 |
| Chong, CR | 1 |
| Ramaiya, NH | 1 |
| Gray, SW | 1 |
| Marcoux, JP | 1 |
| Hatabu, H | 1 |
| Jänne, PA | 1 |
| Hodi, FS | 1 |
| Awad, MM | 1 |
| Syrigos, K | 1 |
| Tsagouli, S | 1 |
| Grapsa, D | 1 |
| Kashiwabara, K | 1 |
| Semba, H | 1 |
| Fujii, S | 1 |
| Tsumura, S | 1 |
| Goto, Y | 1 |
| Hojo, M | 1 |
| Takeda, Y | 1 |
| Kobayashi, N | 1 |
| Kudo, K | 1 |
| Chatzikyrkou, C | 1 |
| Hamwi, I | 1 |
| Clajus, C | 1 |
| Becker, J | 1 |
| Hafer, C | 1 |
| Kielstein, JT | 1 |
| Ko, JH | 1 |
| Shih, YC | 1 |
| Hui, RC | 1 |
| Yang, CH | 1 |
| Narita, Y | 1 |
| Etienne, B | 1 |
| Pérol, M | 2 |
| Nesme, P | 1 |
| Vuillermoz, S | 1 |
| Robinet, G | 2 |
| Guérin, JC | 1 |
| Thomas, P | 1 |
| Vergnenègre, A | 1 |
| Lena, H | 1 |
| Taytard, A | 1 |
| Paillotin, D | 1 |
| Bessa, EH | 1 |
| Schuller-Lebeau, MP | 1 |
| Nakao, I | 1 |
| Ohashi, Y | 1 |
| Ito, K | 1 |
| Yokoyama, T | 1 |
| Nishi, I | 1 |
| Kanko, T | 1 |
| Saito, T | 1 |
| Watanabe, A | 1 |
| Horio, Y | 1 |
| Minami, H | 1 |
| Shibagaki, T | 1 |
| Iwahara, T | 1 |
| Sakai, S | 1 |
| Shimokata, K | 1 |
| Rapp, E | 1 |
| Pater, JL | 1 |
| Willan, A | 1 |
| Cormier, Y | 1 |
| Murray, N | 1 |
| Evans, WK | 1 |
| Hodson, DI | 1 |
| Clark, DA | 1 |
| Feld, R | 1 |
| Arnold, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Non-small Cell Lung Cancer Patients[NCT03803787] | Phase 2 | 72 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for prednisolone and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell L | 2019 |
[Chemotherapy for brain metastases].
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasm | 2005 |
3 trials available for prednisolone and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Che | 2015 |
[Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplast | 2000 |
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical | 1988 |
28 other studies available for prednisolone and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Case report: immune-mediated cerebellar ataxia secondary to anti-PD-L1 treatment for lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Car | 2019 |
Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report.
Topics: Aged; Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Herpes Zoster Oticus; Humans; Lung Neoplasms | 2019 |
Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab.
Topics: Adenocarcinoma of Lung; Adrenal Gland Neoplasms; Antineoplastic Agents, Immunological; Brain Neoplas | 2020 |
Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Non-Small- | 2020 |
Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2020 |
Pemetrexed-induced pseudocellulitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clo | 2020 |
Durvalumab-associated vasculitis presenting as 'the blue toe syndrome'.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Blue Toe Syndrome; | 2020 |
Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Pro | 2021 |
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Cholangiopancreat | 2021 |
Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review.
Topics: Aged; Antibodies, Monoclonal; Autoantibodies; Blepharoptosis; Carcinoma, Non-Small-Cell Lung; Creati | 2017 |
Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcin | 2018 |
Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Asian P | 2018 |
A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactio | 2019 |
[Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Carcinoma, | 2019 |
Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lu | 2019 |
Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis.
Topics: Aged; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Glucocortico | 2019 |
Enhanced white adipose tissue metabolism in iatrogenic Cushing's syndrome with FDG PET/CT.
Topics: Adipose Tissue, White; Adolescent; Adult; Carcinoma, Non-Small-Cell Lung; Cushing Syndrome; Dexameth | 2014 |
Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease.
Topics: Aged; Antineoplastic Agents, Hormonal; Bronchoalveolar Lavage Fluid; Bronchoscopy; Carcinoma, Non-Sm | 2014 |
Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-centre experience.
Topics: Administration, Inhalation; Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell | 2016 |
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; Carci | 2016 |
Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient With Advanced Non-Small Cell Lung Cancer: A Case Report.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Non-Small-Cel | 2016 |
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Comb | 2017 |
Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cyclophos | 2010 |
Biopsy proven acute interstitial nephritis after treatment with moxifloxacin.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aza Compounds; Biopsy; Carcino | 2010 |
Necrotizing vasculitis triggered by gefitinib: an unusual clinical presentation.
Topics: Antineoplastic Agents; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Follow-Up Studies; Gefitinib; | 2011 |
[Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases].
Topics: Aged; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; C | 1998 |
[Combination chemotherapy of non-small cell lung cancer (NSCLC) with cisplatin (CDDP), carboquone (CQ) and prednisolone (PDN)(PPQ therapy)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carbazilqu | 1990 |
[A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis].
Topics: Administration, Oral; Adult; Aged; Alprazolam; Antineoplastic Combined Chemotherapy Protocols; Carci | 1990 |